Quick Answer
TriSalus Life Sciences, Inc. reported Gross Profit of $38.19 million for the year ending 2025.
- TriSalus Life Sciences, Inc. showed an increase of +50.8% in Gross Profit from 2024 to 2025.
- This data is from TriSalus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $3.22 million | Q1 2023: $2.32 million | Q2 2023: $3.84 million | Q3 2023: $4.60 million | Q1 2024: $5.49 million | Q2 2024: $6.45 million | Q3 2024: $6.35 million | Q1 2025: $7.67 million | Q2 2025: $9.41 million | Q3 2025: $9.66 million.
- Over the full 4 years of available data (2022 to 2025), TriSalus Life Sciences, Inc.'s Gross Profit has grown by 276.6%.
- Historical annual values: Fiscal year 2025: $38.19 million | Fiscal year 2024: $25.33 million | Fiscal year 2023: $15.91 million | Fiscal year 2022: $10.14 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: